Latest Radiation oncology Stories
SALT LAKE CITY, May 22, 2013 /PRNewswire/ -- Varian Medical Systems (NYSE:VAR) today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Varian's diagnostic X-ray image processing workstation that combines radio frequency (RF) and digital radiography (DR) capabilities on one platform. Varian's Nexus DRF Digital X-Ray Imaging System(TM) has the ability to interface with a variety of image receptors, including CCD cameras and commercially...
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA Department of Urology. The study reports the 14-year survival outcomes of 3,000 men diagnosed with prostate cancer between 1994 and 1995. The results suggest that older patients with low- to intermediate-risk prostate cancer and who have at least three underlying health...
IASIS MEDICAL Sees Substantial Opportunity In Offering IsoRay's Entire Product Line RICHLAND, Wash., May 21, 2013 /PRNewswire/ -- IsoRay, Inc. (AMEX: ISR), (http://www.isoray.com/), announced today that it has entered into an exclusive international distribution agreement with IASIS Medical for the sale of IsoRay's complete product line in Greece. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung...
Updated ASTRO Model Policy Endorses Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer SUNNYVALE, Calif., May 21, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy (SBRT). The study followed 304 patients for a median of 5 years, and many...
GLENWOOD, Ill., May 20, 2013 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, announced today that its Board of Directors declared, at its meeting on May 16, 2013, a regular quarterly cash dividend of $0.55 per share for the third quarter of fiscal 2013. The dividend will be paid on July 3, 2013, to shareholders of...
Linear accelerator is island's first Versa HD PONCE, Puerto Rico, May 17, 2013 /PRNewswire/ -- Serving a region of 650,000 inhabitants in southern, central and western Puerto Rico, Caribbean Imaging and Radiation Therapy (CIRT, Ponce, PR) Center has improved its radiation therapy capabilities with the acquisition of an Elekta Versa HD(TM) system, the first in Puerto Rico. Versa HD offers clinicians the versatility to deliver conventional therapies to treat a wide range of tumors...
The first and only hardware and software upgrade available for Siemens ECAT 47, ECAT HR+, and ECAT Accel PET systems HOUSTON, May 15, 2013 /PRNewswire-iReach/ -- Medical Imaging Electronics (MiE) and Nuclear Imaging Services (NIS) are pleased to announce that the ECAT Scintron has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). MiE along with NIS will showcase this product at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in...
[311 Pages Report] The Radiotherapy Devices Market Report segments global market of Monitoring Devices by various technologies Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Cyber knife, Gamma knife, Proton / Neutron Therapy, Dynamic Multi-Leaf Collimator (DMLC) and by Geography (PRWEB) May 10, 2013 The “Radiotherapy Market By Technology, Applications & Products (2011 – 2016)”, published by MarketsandMarkets analyzes and studies the major...
Research projects to have implications for cancer treatment worldwide TORONTO, May 10, 2013 /PRNewswire/ -- Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (Toronto, Canada) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy. Sunnybrook Health Sciences Centre, the sixth largest cancer center in North America, is the fourth member to sign the research...
In a retrospective study recently online by The Oncologist, Jason Faris, M.D., Medical Oncologist at the Massachusetts General Hospital Cancer Center in Boston, and colleagues described their institutional experience with the FOLFIRINOX treatment protocol in patients with locally advanced pancreatic cancer. Durham, NC (PRWEB) May 08, 2013 Treatment with neoadjuvant 5-FU, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) followed by chemoradiation shows substantial activity in patients...
